REFERENCES
1. WorldObesity.org. One billion people globally estimated to be living with obesity by 2030. Available from: https://www.worldobesity.org/resources/resource-library/world-obesity-atlas-2022 [Last accessed on 12 Jun 2023].
2. Safaei M, Sundararajan EA, Driss M, Boulila W, Shapi'i A. A systematic literature review on obesity: understanding the causes & consequences of obesity and reviewing various machine learning approaches used to predict obesity. Comput Biol Med 2021;136:104754.
3. Bischoff SC, Boirie Y, Cederholm T, et al. Towards a multidisciplinary approach to understand and manage obesity and related diseases. Clin Nutr 2017;36:917-38.
4. Stanford FC, Tauqeer Z, Kyle TK. Media and its influence on obesity. Curr Obes Rep 2018;7:186-92.
5. Vecchié A, Dallegri F, Carbone F, et al. Obesity phenotypes and their paradoxical association with cardiovascular diseases. Eur J Intern Med 2018;48:6-17.
6. Schulze MB. Metabolic health in normal-weight and obese individuals. Diabetologia 2019;62:558-66.
7. Leisegang K, Henkel R, Agarwal A. Obesity and metabolic syndrome associated with systemic inflammation and the impact on the male reproductive system. Am J Reprod Immunol 2019;82:e13178.
8. Corona G, Goulis DG, Huhtaniemi I, et al. European academy of andrology (EAA) guidelines on investigation, treatment and monitoring of functional hypogonadism in males: endorsing organization: European society of endocrinology. Andrology 2020;8:970-87.
9. Gurayah AA, Mason MM, Masterson JM, Kargi AY, Ramasamy R. U-shaped association between prevalence of secondary hypogonadism and body mass index: a retrospective analysis of men with testosterone deficiency. Int J Impot Res 2023;35:374-7.
10. Rastrelli G, Carter EL, Ahern T, et al. EMAS Study Group. Development of and recovery from secondary hypogonadism in aging men: prospective results from the EMAS. J Clin Endocrinol Metab 2015;100:3172-82.
11. Tajar A, Forti G, O'Neill TW, et al. EMAS Group. Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study. J Clin Endocrinol Metab 2010;95:1810-8.
12. Aggerholm AS, Thulstrup AM, Toft G, Ramlau-Hansen CH, Bonde JP. Is overweight a risk factor for reduced semen quality and altered serum sex hormone profile? Fertil Steril 2008;90:619-26.
13. Calderón B, Galdón A, Calañas A, et al. Effects of bariatric surgery on male obesity-associated secondary hypogonadism: comparison of laparoscopic gastric bypass with restrictive procedures. Obes Surg 2014;24:1686-92.
14. Calderón B, Gómez-Martín JM, Vega-Piñero B, et al. Prevalence of male secondary hypogonadism in moderate to severe obesity and its relationship with insulin resistance and excess body weight. Andrology 2016;4:62-7.
15. Dhindsa S, Bhatia V, Dhindsa G, et al. The effects of hypogonadism on body composition and bone mineral density in type 2 diabetic patients. Diabetes Care 2007;30:1860-1.
16. Escobar-Morreale HF, Santacruz E, Luque-Ramírez M, Botella Carretero JI. Prevalence of 'obesity-associated gonadal dysfunction' in severely obese men and women and its resolution after bariatric surgery: a systematic review and meta-analysis. Hum Reprod Update 2017;23:390-408.
17. Hofstra J, Loves S, van Wageningen B, et al. High prevalence of hypogonadotropic hypogonadism in men referred for obesity treatment. Neth J Med 2008;66:103-109.
18. Rigon FA, Ronsoni MF, Hohl A, van de Sande-Lee S. Effects of bariatric surgery in male obesity-associated hypogonadism. Obes Surg 2019;29:2115-25.
19. Wu FC, Tajar A, Beynon JM, et al. EMAS Group. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 2010;363:123-35.
20. Dhindsa S, Ghanim H, Jenkins T, et al. High prevalence of subnormal testosterone in obese adolescent males: reversal with bariatric surgery. Eur J Endocrinol 2022;186:319-27.
21. van Hulsteijn LT, Pasquali R, Casanueva F, et al. Prevalence of endocrine disorders in obese patients: systematic review and meta-analysis. Eur J Endocrinol 2020;182:11-21.
22. Bonomi M, Vezzoli V, Krausz C, et al. Italian Network on Central Hypogonadism. Characteristics of a nationwide cohort of patients presenting with isolated hypogonadotropic hypogonadism (IHH). Eur J Endocrinol 2018;178:23-32.
23. Kapoor D, Aldred H, Clark S, Channer KS, Jones TH. Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity. Diabetes Care 2007;30:911-7.
24. Liu CC, Wu WJ, Lee YC, et al. The prevalence of and risk factors for androgen deficiency in aging Taiwanese men. J Sex Med 2009;6:936-46.
25. Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract 2006;60:762-9.
26. Fernandez CJ, Chacko EC, Pappachan JM. Male obesity-related secondary hypogonadism - pathophysiology, clinical implications and management. Eur Endocrinol 2019;15:83-90.
27. Genchi VA, Rossi E, Lauriola C, et al. Adipose tissue dysfunction and obesity-related male hypogonadism. Int J Mol Sci 2022;23:8194.
28. Carrageta DF, Oliveira PF, Alves MG, Monteiro MP. Obesity and male hypogonadism: tales of a vicious cycle. Obes Rev 2019;20:1148-58.
29. Kawai T, Autieri MV, Scalia R. Adipose tissue inflammation and metabolic dysfunction in obesity. Am J Physiol Cell Physiol 2021;320:C375-91.
30. Yazıcı D, Sezer H. Insulin resistance, obesity and lipotoxicity. Adv Exp Med Biol 2017;960:277-304.
31. Grossmann M, Ng Tang Fui M, Cheung AS. Late-onset hypogonadism: metabolic impact. Andrology 2020;8:1519-29.
32. Harris RB. Direct and indirect effects of leptin on adipocyte metabolism. Biochim Biophys Acta 2014;1842:414-23.
33. Parent AS, Lebrethon MC, Gérard A, Vandersmissen E, Bourguignon JP. Leptin effects on pulsatile gonadotropin releasing hormone secretion from the adult rat hypothalamus and interaction with cocaine and amphetamine regulated transcript peptide and neuropeptide Y. Regul Pept 2000;92:17-24.
34. Quennell JH, Mulligan AC, Tups A, et al. Leptin indirectly regulates gonadotropin-releasing hormone neuronal function. Endocrinology 2009;150:2805-12.
35. Marcouiller F, Jochmans-Lemoine A, Ganouna-Cohen G, et al. Metabolic responses to intermittent hypoxia are regulated by sex and estradiol in mice. Am J Physiol Endocrinol Metab 2021;320:E316-25.
36. Ishikawa T, Fujioka H, Ishimura T, Takenaka A, Fujisawa M. Expression of leptin and leptin receptor in the testis of fertile and infertile patients. Andrologia 2007;39:22-7.
37. Giovambattista A, Suescun MO, Nessralla CC, et al. Modulatory effects of leptin on leydig cell function of normal and hyperleptinemic rats. Neuroendocrinology 2003;78:270-9.
38. Khodamoradi K, Khosravizadeh Z, Seetharam D, et al. The role of leptin and low testosterone in obesity. Int J Impot Res 2022;34:704-13.
40. Aftab SA, Kumar S, Barber TM. The role of obesity and type 2 diabetes mellitus in the development of male obesity-associated secondary hypogonadism. Clin Endocrinol 2013;78:330-7.
41. Cohen PG. Aromatase, adiposity, aging and disease. the hypogonadal-metabolic-atherogenic-disease and aging connection. Med Hypotheses 2001;56:702-8.
42. Grossmann M. Testosterone and glucose metabolism in men: current concepts and controversies. J Endocrinol 2014;220:R37-55.
43. Grossmann M. Hypogonadism and male obesity: focus on unresolved questions. Clin Endocrinol 2018;89:11-21.
44. Childs GV, Odle AK, MacNicol MC, MacNicol AM. The importance of leptin to reproduction. Endocrinology 2021:162.
45. Jamieson BB, Piet R. Kisspeptin neuron electrophysiology: Intrinsic properties, hormonal modulation, and regulation of homeostatic circuits. Front Neuroendocrinol 2022;66:101006.
46. Ghaderpour S, Ghiasi R, Heydari H, Keyhanmanesh R. The relation between obesity, kisspeptin, leptin, and male fertility. Horm Mol Biol Clin Investig 2021;43:235-47.
47. Anawalt BD, Matsumoto AM. Aging and androgens: physiology and clinical implications. Rev Endocr Metab Disord 2022;23:1123-37.
48. Barber TM, Kyrou I, Kaltsas G, et al. Mechanisms of central hypogonadism. Int J Mol Sci 2021;22:8217.
49. Ahmad R, Haque M. Obesity: a doorway to a molecular path leading to infertility. Cureus 2022;14:e30770.
50. Chang B, Song C, Gao H, et al. Leptin and inflammatory factors play a synergistic role in the regulation of reproduction in male mice through hypothalamic kisspeptin-mediated energy balance. Reprod Biol Endocrinol 2021;19:12.
51. Braga PC, Pereira SC, Ribeiro JC, et al. Late-onset hypogonadism and lifestyle-related metabolic disorders. Andrology 2020;8:1530-8.
52. Xie Q, Kang Y, Zhang C, et al. The role of kisspeptin in the control of the hypothalamic-pituitary-gonadal axis and reproduction. Front Endocrinol 2022;13:925206.
53. Tremellen K. Gut endotoxin leading to a decline in gonadal function (GELDING) - a novel theory for the development of late onset hypogonadism in obese men. Basic Clin Androl 2016;26:7.
54. Santacroce L, Imbimbo C, Ballini A, et al. Testicular immunity and its connection with the microbiota. physiological and clinical implications in the light of personalized medicine. J Pers Med 2022;12:1335.
55. Pearce KL, Hill A, Tremellen KP. Obesity related metabolic endotoxemia is associated with oxidative stress and impaired sperm DNA integrity. Basic Clin Androl 2019;29:6.
56. Barber TM, Valsamakis G, Mastorakos G, et al. Dietary influences on the microbiota-gut-brain axis. Int J Mol Sci 2021;22:3502.
57. Dimopoulou C, Goulis DG, Corona G, Maggi M. The complex association between metabolic syndrome and male hypogonadism. Metabolism 2018;86:61-8.
58. Rastrelli G, Filippi S, Sforza A, Maggi M, Corona G. Metabolic Syndrome in Male Hypogonadism. In: Popovic V, Korbonits M, editors. Metabolic syndrome consequent to endocrine disorders. S. Karger AG; 2018. pp. 131-55.
59. Mangiola S, Stuchbery R, McCoy P, et al. Androgen deprivation therapy promotes an obesity-like microenvironment in periprostatic fat. Endocr Connect 2019;8:547-58.
60. Boban M. Cardiovascular diseases and androgen deprivation therapy. Acta Clin Croat 2019;58:60-3.
61. Bhasin S, Taylor WE, Singh R, et al. The mechanisms of androgen effects on body composition: mesenchymal pluripotent cell as the target of androgen action. J Gerontol A Biol Sci Med Sci 2003;58:M1103-10.
62. Herbst KL, Bhasin S. Testosterone action on skeletal muscle. Curr Opin Clin Nutr Metab Care 2004;7:271-7.
63. Singh R, Artaza JN, Taylor WE, Gonzalez-Cadavid NF, Bhasin S. Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway. Endocrinology 2003;144:5081-8.
65. Xu XF, De Pergola G, Björntorp P. Testosterone increases lipolysis and the number of beta-adrenoceptors in male rat adipocytes. Endocrinology 1991;128:379-82.
66. Pergola G. The adipose tissue metabolism: role of testosterone and dehydroepiandrosterone. Int J Obes Relat Metab Disord 2000;24 Suppl 2:S59-63.
67. Hernández-Morante JJ, Pérez-de-Heredia F, Luján JA, Zamora S, Garaulet M. Role of DHEA-S on body fat distribution: gender- and depot-specific stimulation of adipose tissue lipolysis. Steroids 2008;73:209-15.
69. M.; Mårin, P.; Björntorp, P. Effect of testosterone on abdominal adipose tissue in men. Int J Obes 1991;15:791-795.
70. Mårin P, Lönn L, Andersson B, et al. Assimilation of triglycerides in subcutaneous and intraabdominal adipose tissues
71. Kim S, Kwon H, Park JH, et al. A low level of serum total testosterone is independently associated with nonalcoholic fatty liver disease. BMC Gastroenterol 2012;12:69.
72. Stellato RK, Feldman HA, Hamdy O, Horton ES, McKinlay JB. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study. Diabetes Care 2000;23:490-4.
73. Lugari S, Baldelli E, Lonardo A. Metabolic primary liver cancer in adults: risk factors and pathogenic mechanisms. Metab Target Organ Damage 2023;3:5.
74. Hawksworth DJ, Burnett AL. nonalcoholic fatty liver disease, male sexual dysfunction, and infertility: common links, common problems. Sex Med Rev 2020;8:274-85.
75. Yim JY, Kim J, Kim D, Ahmed A. Serum testosterone and non-alcoholic fatty liver disease in men and women in the US. Liver Int 2018;38:2051-9.
76. Jaruvongvanich V, Sanguankeo A, Riangwiwat T, Upala S. Testosterone, sex hormone-binding globulin and nonalcoholic fatty liver disease: a systematic review and meta-analysis. Annals of Hepatology 2017;16:382-94.
77. Lazo M, Zeb I, Nasir K, et al. Association between endogenous sex hormones and liver fat in a multiethnic study of atherosclerosis. Clin Gastroenterol Hepatol 2015;13:1686-93.e2.
78. Charlton M, Angulo P, Chalasani N, et al. Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease. Hepatology 2008;47:484-92.
79. Koehler E, Swain J, Sanderson S, et al. Growth hormone, dehydroepiandrosterone and adiponectin levels in non-alcoholic steatohepatitis: an endocrine signature for advanced fibrosis in obese patients. Liver Int 2012;32:279-86.
80. Wang WB, She F, Xie LF, et al. Evaluation of basal serum adrenocorticotropic hormone and cortisol levels and their relationship with nonalcoholic fatty liver disease in male patients with idiopathic hypogonadotropic hypogonadism. Chin Med J 2016;129:1147-53.
81. Lonardo A, Carani C, Carulli N, Loria P. 'Endocrine NAFLD' a hormonocentric perspective of nonalcoholic fatty liver disease pathogenesis. J Hepatol 2006;44:1196-207.
82. Bobjer J, Katrinaki M, Tsatsanis C, Lundberg Giwercman Y, Giwercman A. Negative association between testosterone concentration and inflammatory markers in young men: a nested cross-sectional study. PLoS One 2013;8:e61466.
83. Ebrahimi F, Urwyler SA, Straumann S, et al. IL-1 antagonism in men with metabolic syndrome and low testosterone: a randomized clinical trial. J Clin Endocrinol Metab 2018;103:3466-76.
84. Willis SA, Bawden SJ, Malaikah S, et al. The role of hepatic lipid composition in obesity-related metabolic disease. Liver Int 2021;41:2819-35.
85. Mody A, White D, Kanwal F, Garcia JM. Relevance of low testosterone to non-alcoholic fatty liver disease. Cardiovasc Endocrinol 2015;4:83-9.
86. Seo NK, Koo HS, Haam JH, et al. Prediction of prevalent but not incident non-alcoholic fatty liver disease by levels of serum testosterone. J Gastroenterol Hepatol 2015;30:1211-6.
87. Barbonetti A, Caterina Vassallo MR, Cotugno M, et al. Low testosterone and non-alcoholic fatty liver disease: evidence for their independent association in men with chronic spinal cord injury. J Spinal Cord Med 2016;39:443-9.
88. Gild P, Cole AP, Krasnova A, et al. Liver disease in men undergoing androgen deprivation therapy for prostate cancer. J Urol 2018;200:573-81.
89. Albhaisi S, Kim K, Baker J, et al. LPCN 1144 resolves NAFLD in hypogonadal males. Hepatol Commun 2020;4:1430-40.
90. Sakr HF, Hussein AM, Eid EA, AlKhateeb M. Possible mechanisms underlying fatty liver in a rat model of male hypogonadism: a protective role for testosterone. Steroids 2018;135:21-30.
91. Schleich F, Legros JJ. Effects of androgen substitution on lipid profile in the adult and aging hypogonadal male. Eur J Endocrinol 2004;151:415-24.
92. Peters JM, Zhou YC, Ram PA, et al. Peroxisome proliferator-activated receptor alpha required for gene induction by dehydroepiandrosterone-3 beta-sulfate. Mol Pharmacol 1996;50:67-74.
93. Lonardo A, Mantovani A, Lugari S, Targher G. NAFLD in some common endocrine diseases: prevalence, pathophysiology, and principles of diagnosis and management. Int J Mol Sci 2019;20:2841.
94. Loria P, Carulli L, Bertolotti M, Lonardo A. Endocrine and liver interaction: the role of endocrine pathways in NASH. Nat Rev Gastroenterol Hepatol 2009;6:236-47.
95. Harada N, Hanaoka R, Hanada K, et al. Hypogonadism alters cecal and fecal microbiota in male mice. Gut Microbes 2016;7:533-9.
96. Liebe R, Esposito I, Bock HH, et al. Diagnosis and management of secondary causes of steatohepatitis. J Hepatol 2021;74:1455-71.
97. Huh JH, Kim KJ, Kim SU, et al. Obesity is more closely related with hepatic steatosis and fibrosis measured by transient elastography than metabolic health status. Metabolism 2017;66:23-31.
98. Lonardo A, Mantovani A, Lugari S, Targher G. Epidemiology and pathophysiology of the association between NAFLD and metabolically healthy or metabolically unhealthy obesity. Ann Hepatol 2020;19:359-66.
99. Man S, Lv J, Yu C, et al. Association between metabolically healthy obesity and non-alcoholic fatty liver disease. Hepatol Int 2022;16:1412-23.
100. Kouvari M, Chrysohoou C, Skoumas J, et al. ATTICA study Investigators. The presence of NAFLD influences the transition of metabolically healthy to metabolically unhealthy obesity and the ten-year cardiovascular disease risk: a population-based cohort study. Metabolism 2022;128:154893.
101. Kouvari M, Panagiotakos DB, Yannakoulia M, et al. ATTICA study investigators. Transition from metabolically benign to metabolically unhealthy obesity and 10-year cardiovascular disease incidence: the ATTICA cohort study. Metabolism 2019;93:18-24.
102. Nead KT. Androgens and depression: a review and update. Curr Opin Endocrinol Diabetes Obes 2019;26:175-9.
103. Vermeer A, Riečanský I, Eisenegger C. Competition, testosterone, and adult neurobehavioral plasticity. Prog Brain Res 2016;229:213-238.
104. Yang L, Zhou R, Tong Y, et al. Neuroprotection by dihydrotestosterone in LPS-induced neuroinflammation. Neurobiol Dis 2020;140:104814.
105. Wang H, He Y, Sun Z, et al. Microglia in depression: an overview of microglia in the pathogenesis and treatment of depression. J Neuroinflammation 2022;19:132.
106. Sallam MY, El-Gowilly SM, El-Mas MM. Androgenic modulation of arterial baroreceptor dysfunction and neuroinflammation in endotoxic male rats. Brain Res 2021;1756:147330.
107. Westley CJ, Amdur RL, Irwig MS. High rates of depression and depressive symptoms among men referred for borderline testosterone Levels. J Sex Med 2015;12:1753-60.
108. Karolczak K, Kostanek J, Soltysik B, et al. Relationships between plasma concentrations of testosterone and dihydrotestosterone and geriatric depression scale scores in men and women aged 60-65 years-a multivariate approach with the use of quade’s test. Int J Environ Res Public Health 2022;19:12507.
109. Makhlouf AA, Mohamed MA, Seftel AD, Niederberger C. Hypogonadism is associated with overt depression symptoms in men with erectile dysfunction. Int J Impot Res 2008;20:157-61.
110. Younossi ZM, Paik JM, Golabi P, et al. The impact of fatigue on mortality of patients with non-alcoholic fatty liver disease: data from national health and nutrition examination survey 2005-2010 and 2017-2018. Liver Int 2022;42:2646-61.
111. Surdea-Blaga T, Dumitraşcu DL. Depression and anxiety in nonalcoholic steatohepatitis: is there any association? Rom J Intern Med 2011;49:273-280.
112. Colognesi M, Gabbia D, De Martin S. Depression and cognitive impairment-extrahepatic manifestations of NAFLD and NASH. Biomedicines 2020;8:229.
113. Lonardo A, Ballestri S. Perspectives of nonalcoholic fatty liver disease research: a personal point of view. Exploration of Medicine 2020;1:85-107.
114. Balzano T, Forteza J, Borreda I, et al. Histological features of cerebellar neuropathology in patients with alcoholic and nonalcoholic steatohepatitis. J Neuropathol Exp Neurol 2018;77:837-45.
115. Giménez-Garzó C, Garcés JJ, Urios A, et al. The PHES battery does not detect all cirrhotic patients with early neurological deficits, which are different in different patients. PLoS One 2017;12:e0171211.
116. Youssef NA, Abdelmalek MF, Binks M, et al. Associations of depression, anxiety and antidepressants with histological severity of nonalcoholic fatty liver disease. Liver Int 2013;33:1062-70.
117. Nocito A, Dahm F, Jochum W, et al. Serotonin mediates oxidative stress and mitochondrial toxicity in a murine model of nonalcoholic steatohepatitis. Gastroenterology 2007;133:608-18.
118. Osawa Y, Kanamori H, Seki E, et al. L-tryptophan-mediated enhancement of susceptibility to nonalcoholic fatty liver disease is dependent on the mammalian target of rapamycin. J Biol Chem 2011;286:34800-8.
119. Abosi O, Lopes S, Schmitz S, Fiedorowicz JG. Cardiometabolic effects of psychotropic medications. Horm Mol Biol Clin Investig 2018:36.
120. Skiba R, Matyjek A, Syryło T, Niemczyk S, Rymarz A. Advanced chronic kidney disease is a strong predictor of hypogonadism and is associated with decreased lean tissue mass. Int J Nephrol Renovasc Dis 2020;13:319-27.
121. Holley JL. The hypothalamic-pituitary axis in men and women with chronic kidney disease. Adv Chronic Kidney Dis 2004;11:337-341.
122. Dunkel L, Raivio T, Laine J, Holmberg C. Circulating luteinizing hormone receptor inhibitor(s) in boys with chronic renal failure. Kidney Int 1997;51:777-84.
123. Schmidt A, Luger A, Hörl WH. Sexual hormone abnormalities in male patients with renal failure. Nephrol Dial Transplant 2002;17:368-71.
124. Peces R, Horcajada C, López-Novoa JM, et al. Hyperprolactinemia in chronic renal failure: impaired responsiveness to stimulation and suppression. normalization after transplantation. Nephron 1981;28:11-6.
125. Romejko K, Rymarz A, Sadownik H, Niemczyk S. Testosterone deficiency as one of the major endocrine disorders in chronic kidney disease. Nutrients 2022;14:3438.
126. Fukui M, Kitagawa Y, Ose H, Hasegawa G, Yoshikawa T, Nakamura N. Role of endogenous androgen against insulin resistance and athero- sclerosis in men with type 2 diabetes. Curr Diabetes Rev 2007;3:25-31.
127. Pivonello R, Menafra D, Riccio E, et al. Metabolic Disorders and male hypogonadotropic hypogonadism. Front Endocrinol 2019;10:345.
128. Fang T, Zhang Q, Wang Y, Zha H. Diagnostic value of visceral adiposity index in chronic kidney disease: a meta-analysis. Acta Diabetol 2023;60:739-48.
129. Zheng X, Han L, Shen S, Wu W. Association between visceral adiposity index and chronic kidney disease: evidence from the china health and retirement longitudinal study. Nutr Metab Cardiovasc Dis 2022;32:1437-44.
130. Cobo G, Cordeiro AC, Amparo FC, et al. Visceral adipose tissue and leptin hyperproduction are associated with hypogonadism in men with chronic kidney disease. J Ren Nutr 2017;27:243-8.
131. Navaneethan SD, Kirwan JP, Remer EM, et al. CRIC Study Investigators. Adiposity, physical function, and their associations with insulin resistance, inflammation, and adipokines in CKD. Am J Kidney Dis 2021;77:44-55.
132. Lonardo A, Mantovani A, Targher G, Baffy G. Nonalcoholic fatty liver disease and chronic kidney disease: epidemiology, pathogenesis, and clinical and research implications. Int J Mol Sci 2022;23:13320.
133. Kim SD, Cho KS. Obstructive sleep apnea and testosterone deficiency. World J Mens Health 2019;37:12-8.
134. Wittert G. The relationship between sleep disorders and testosterone. Curr Opin Endocrinol Diabetes Obes 2014;21:239-43.
135. Luboshitzky R, Zabari Z, Shen-Orr Z, Herer P, Lavie P. Disruption of the nocturnal testosterone rhythm by sleep fragmentation in normal men. J Clin Endocrinol Metab 2001;86:1134-9.
136. Luboshitzky R, Aviv A, Hefetz A, et al. Decreased pituitary-gonadal secretion in men with obstructive sleep apnea. J Clin Endocrinol Metab 2002;87:3394-8.
137. Chen Y, Zhang L, Zhao S, et al. Association of night-time sleep and day napping with the prevalence of MOSH in young obese men. Andrology 2021;9:1872-8.
138. De Lorenzo A, Noce A, Moriconi E, et al. MOSH syndrome (Male Obesity Secondary Hypogonadism): clinical assessment and possible therapeutic approaches. Nutrients 2018;10:474.
139. Corona G, Rastrelli G, Monami M, et al. Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. Eur J Endocrinol 2013;168:829-43.
140. Pellitero S, Olaizola I, Alastrue A, et al. Hypogonadotropic hypogonadism in morbidly obese males is reversed after bariatric surgery. Obes Surg 2012;22:1835-42.
141. Miñambres I, Sardà H, Urgell E, et al. Obesity surgery improves hypogonadism and sexual function in men without effects in sperm quality. J Clin Med 2022;11:5126.
142. Furini C, Spaggiari G, Simoni M, Greco C, Santi D. Ketogenic state improves testosterone serum levels-results from a systematic review and meta-analysis. Endocrine 2023;79:273-82.
143. Al Qurashi AA, Qadri SH, Lund S, et al. The effects of bariatric surgery on male and female fertility: A systematic review and meta-analysis. Ann Med Surg 2022;80:103881.
144. Wei Y, Chen Q, Qian W. Effect of bariatric surgery on semen parameters: a systematic review and meta-analysis. Med Sci Monit Basic Res 2018;24:188-97.
145. Samavat J, Cantini G, Lotti F, et al. Massive weight loss obtained by bariatric surgery affects semen quality in morbid male obesity: a preliminary prospective double-armed study. Obes Surg 2018;28:69-76.
146. Wood GJA, Tiseo BC, Paluello DV, et al. Bariatric surgery impact on reproductive hormones, semen analysis, and sperm DNA fragmentation in men with severe obesity: prospective study. Obes Surg 2020;30:4840-51.
147. Colleluori G, Chen R, Turin CG, et al. Aromatase inhibitors plus weight loss improves the hormonal profile of obese hypogonadal men without causing major side effects. Front Endocrinol 2020;11:277.
148. Shah T, Nyirenda T, Shin D. Efficacy of anastrozole in the treatment of hypogonadal, subfertile men with body mass index ≥ 25 kg/m2. Transl Androl Urol 2021;10:1222-8.
149. Lapauw B, Kaufman JM. Management of endocrine disease: rationale and current evidence for testosterone therapy in the management of obesity and its complications. Eur J Endocrinol 2020;183:R167-83.
150. Caliber M, Hackett G. Important lessons about testosterone therapy- weight loss vs. testosterone therapy for symptom resolution, classical
151. Isidori AM, Aversa A, Calogero A, et al. Adult- and late-onset male hypogonadism: the clinical practice guidelines of the Italian society of andrology and sexual medicine (SIAMS) and the Italian society of endocrinology (SIE). J Endocrinol Invest 2022;45:2385-403.
